A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)

Date de début de l'étude : 1 mars 2008

Inclusion criteria: Patients may be included in the study if they meet all of the following criteria: * Patients must have confirmed diagnosis of HL or NHL (follicular, marginal zone / MALT, diffuse large B-cell, or mantle cell) per REAL/WHO classification * Patients must have progressed after at least 2 prior therapies (autologous stem cell transplantation is considered as 1 therapy) * Patients must be ≥ 18 years * Patients must have life expectancy \> 3 months * Patient must have adequate laboratory results * Patients must have WHO Performance Status grade 0, 1, or 2 * Patients must have at least one site of measurable disease * Patients must have discontinued any previous monoclonal antibody or radioimmunotherapy, and must have recovered fully from the side effects of that treatment prior to beginning study treatment. * Patients must be willing and able to sign the informed consent form and comply with the study protocol Exclusion criteria: Patients will be excluded from the study if they meet any of the following criteria: * Patients who have been treated with any anti-CD40 antibody * Patients who have received prior allogeneic stem cell transplant * Patients who have had a prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration * Patients who have history or clinical evidence of central nervous system, meningeal, or epidural disease including brain metastasis * Women of child-bearing potential (WCBP) who are pregnant or breast feeding. Other protocol-defined inclusion/exclusion criteria may apply